0001104659-24-027499.txt : 20240226 0001104659-24-027499.hdr.sgml : 20240226 20240226160929 ACCESSION NUMBER: 0001104659-24-027499 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240220 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PepperLime Health Acquisition Corp CENTRAL INDEX KEY: 0001873324 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40915 FILM NUMBER: 24678781 BUSINESS ADDRESS: STREET 1: 548 MARKET STREET STREET 2: PMB 97425 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 263-9939 MAIL ADDRESS: STREET 1: 548 MARKET STREET STREET 2: PMB 97425 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 8-K 1 tm247248d1_8k.htm FORM 8-K
false 0001873324 00-0000000 0001873324 2024-02-20 2024-02-20 0001873324 PEPL:UnitseachconsistingofoneClassAordinaryshareDollar0.0001parvalueandonehalfofoneredeemableMember 2024-02-20 2024-02-20 0001873324 us-gaap:CommonClassAMember 2024-02-20 2024-02-20 0001873324 PEPL:WarrantseachwholewarrantexercisableforoneClassAordinarysharesMember 2024-02-20 2024-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 20, 2024

 

PepperLime Health Acquisition Corporation

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-40915   N/A
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

548 Market Street, Suite 97425
 San Francisco, CA		   94104
(Address of principal executive offices)   (Zip Code)

 

(415) 263-9939

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title for each class   Trading
Symbol(s)		   Name of each exchange on
which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant   PEPLU   The Nasdaq Stock Market LLC
         
Class A ordinary shares   PEPL   The Nasdaq Stock Market LLC
         
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   PEPLW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On February 21, 2024, PepperLime Health Acquisition Corporation (the “Company”) issued an unsecured promissory note in the aggregate principal amount of up to $77,000 (the “Note”) to PepperOne LLC, the Company’s sponsor (the “Sponsor”). Pursuant to the Note, the Sponsor agreed to loan to the Company an aggregate amount up to $77,000. On February 21, 2024, an initial $40,000 was advanced under the Note. Additional advances of up to the remaining $37,000 of principal amount of the Note may be made upon the request of the Company to the Sponsor anytime before April 19, 2024. The Note does not bear interest. The Company intends to use such funds for working capital purposes.

 

The outstanding principal balance of the Note shall be payable (a) in cash at the closing of any sale by the Sponsor of all or a portion of the Company’s ordinary shares and private warrants it holds to a new sponsor (the “Sponsor Sale”), an amount equal to, at least, the sum of (x) $24,000, and (y) the amount of any advances made under the Note after February 21, 2024; and (b) in cash, or by conversion into the Company’s ordinary shares prior to or concurrently with the closing of a business combination, at the price of $10.00 per share at the option of the Sponsor. In the event that the Company does not consummate a business combination, the Note will be terminated.

 

The foregoing description of the Note is qualified in its entirety by reference to the full text of the Note, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet. Arrangement of a Registrant.

 

The disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

 

Item 8.01 Other Events

 

As previously disclosed, the Company is exploring options other than liquidation. One of these options is a Sponsor Sale although no definitive agreement has been executed as of the date of this report and there is no assurance that one will be entered into before April 19, 2024, the date by which the Company must close a business combination under its current Amended and Restated Memorandum and Articles of Association.

 

On February 20, 2024, the Company deposited $16,277.20 (the “Extension Payment”) into the Company’s trust account in order to extend the date by which the Company has to consummate a business combination to March 19, 2024.

 

Item 9.01 Exhibits.

 

10.1Promissory Note dated February 21, 2024

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks, uncertainties, and assumptions that are difficult to predict. All statements other than statements of historical fact contained in this Current Report on Form 8-K, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” or “should,” or the negative of these terms or other comparable terminology. The forward-looking statements made herein are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history, competitive factors in the Company’s and Force’s industry and market, and other general economic conditions. The forward-looking statements made herein are based on the Company’s current expectations, assumptions, and projections, which could be incorrect. The forward-looking statements made herein speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. The Company cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the Company’s periodic filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and its subsequent Quarterly Report on Form 10-Q. The Company’s SEC filings are available publicly on the SEC’s website at http://www.sec.gov.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PepperLime Health Acquisition Corporation
     
Dated: February 26, 2024 By: /s/  Ramzi Haidamus
    Name: Ramzi Haidamus
    Title: Chief Executive Officer

 

 

 

 EX-10.1 2 tm247248d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: up to $77,000 Dated as of February 21, 2024

 

PepperLime Health Acquisition Corporation (the “Maker”), promises to pay to the order of PepperOne LLC or its registered assigns or successors in interest (the “Payee”) the principal amount of up to seventy seven thousand U.S. Dollars ($77,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

 

1. Principal. An initial forty thousand U.S. Dollars ($40,000) was advanced by Payee to the Maker under this Promissory Note (the “Note”) as of the date hereof.  Additional advances of up to the remaining thirty-seven thousand U.S. Dollars ($37,000) of principal amount of this Note may be made upon the request of Maker to Payee anytime before April 19, 2024. References to the principal balance of this Promissory Note shall be the amount that has been advanced, and not yet repaid.  The outstanding principal balance of this Note shall be payable (a) in cash at the closing of any sale by Payee of all or a portion of the Company’s ordinary shares and private warrants it holds to a new sponsor (the “Sponsor Sale”), an amount equal to, at least, the sum of (x) $24,000, and (y) any amount up to $37,000 advanced after the date hereof; and (b) in cash, or by conversion pursuant to Section 2 hereof, at the option of the Payee, concurrently with the closing of an initial business combination (a “Business Combination”) with a target business (as described in the Maker’s initial public offering prospectus dated October 14, 2021 (the “Prospectus”)). In the event that the Maker is dissolved prior to the closing of a Business Combination, this Note shall be deemed to be terminated and no amounts will thereafter be due from Maker to Payee under the terms hereof. The principal balance may not be prepaid without the consent of the Payee.
   
2. Conversion Rights. Upon notice by the Payee to the Maker at least one business day prior to the closing of a Business Combination that the Payee wishes to convert any remaining principal balance of this Note into ordinary shares of the Maker, the Maker shall cause the remaining principal balance of this Note to be converted into its ordinary shares (the “Shares”) prior to or concurrently with the closing of a Business Combination. The number of Shares to be received by the Payee in connection with such conversion shall be an amount determined by dividing (x) the sum of the remaining principal balance payable to such Payee as of the time of conversion by (y) $10.00.
   
  (a) Fractional Shares. No fractional Shares will be issued upon conversion of this Note. In lieu of any fractional Shares to which Payee would otherwise be entitled, Maker will pay to Payee in cash the amount of the unconverted principal balance of this note that would otherwise be converted into such fractional share.

 

 

 

 

  (b) Effect of Conversion. If the Maker timely receives notice of the Payee’s intention to convert this note, this Note shall be deemed to be converted on the date the Business Combination closes. At its expense, the Maker will, as soon as practicable after receiving this Note for cancellation after the closing of a Business Combination (assuming receipt of timely notice of conversion), issue and deliver to Payee, at Payee’s address set forth on the signature page hereto or such other address requested by Payee, a certificate or certificates for the number of Shares to which Payee is entitled upon such conversion (bearing such legends as are customary pursuant to applicable state and federal securities laws), including a check payable to Payee for any cash amounts payable as a result of any fractional shares as described herein.
     
3. Interest. No interest shall accrue on the unpaid principal balance of this Note.
   
4. Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.
   
5. Events of Default. The following shall constitute an event of default (“Event of Default”):
   
  (a) Failure to Make Required Payments. Failure by Maker to pay the principal of this Note within five (5) business days following the date when due.
     
  (b) Voluntary Liquidation, Etc. The commencement by Maker of a proceeding relating to its bankruptcy, insolvency, reorganization, rehabilitation or other similar action, or the consent by it to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) for Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.
     
  (c) Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of maker in an involuntary case under any applicable bankruptcy, insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) for Maker or for any substantial part of its property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

 

6. Remedies.

 

  (a) Upon the occurrence of an Event of Default specified in Section 5(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.
     
  (b) Upon the occurrence of an Event of Default specified in Sections 5(b) and 5(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

 

 

 

 

7. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.
   
8. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.
   
9. Notices. Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery or (iv) sent by e-mail or facsimile or (v) to the following addresses or to such other address as either party may designate by notice in accordance with this Section:

 

If to Maker:

PepperLime Health Acquisition Corporation
548 Market Street, Suite 97425
San Francisco, California 94104

Attn: Ramzi Haidamus, CEO

e-mail: ramzi@pepperlimehealth.com

 

If to Payee:

PepperOne, LLC
548 Market Street, Suite 97425
San Francisco, California 94104

Attn: Ramzi Haidamus, Manager

e-mail: ramzi@pepperlimehealth.com

 

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile or e-mail transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

 

 

 

 

10. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.
   
11. Jurisdiction. The courts of New York have exclusive jurisdiction to settle any dispute arising out of or in connection with this agreement (including a dispute relating to any non- contractual obligations arising out of or in connection with this agreement) and the parties submit to the exclusive jurisdiction of the courts of New York.
   
12. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
   
13. Trust Waiver. Payee has read the Prospectus and understands that Maker has established the trust account described in the Prospectus for the benefit of the public stockholders and the underwriters of Maker’s initial public offering (the “Underwriters”) and that, except for certain exceptions described in the Prospectus, Maker may disburse monies from the trust account only: (i) to the public stockholders in the event of the conversion of their shares or the liquidation of Maker; or (ii) to Maker and the Underwriters after consummation of a Business Combination.

 

Notwithstanding anything herein to the contrary, Payee hereby agrees that it does not have any right, title, interest or claim of any kind in or to any monies in the trust account (the “Claim”) and hereby waives any Claim it may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with Maker and will not seek recourse against the trust account for any reason whatsoever.

 

14. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.
   
15. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.
   
16. Further Assurance. The Maker shall, at its own cost and expense, execute and do (or procure to be executed and done by any other necessary party) all such deeds, documents, acts and things as the Payee may from time to time require as may be necessary to give full effect to this Promissory Note.

 

 

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by its Chief Executive Officer the day and year first above written.

 

  PepperLime Health Acquisition Corporation
   
  By: /s/ Ramzi Haidamus
  Name:  Ramzi Haidamus
  Title:  Chief Executive Officer

 

Accepted and Agreed:  
   
PepperOne, LLC  
     
By: /s/ Ramzi Haidamus  
Name:  Ramzi Haidamus  
Title:  Manager  

 

 

 

 EX-101.SCH 3 pepl-20240220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pepl-20240220_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 pepl-20240220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Unitseachconsistingofone Class Aordinaryshare Dollar 0. 0001parvalueandonehalfofoneredeemable [Member] Common Class A [Member] Warrantseachwholewarrantexercisableforone Class Aordinaryshares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pepl-20240220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 20, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 20, 2024
Entity File Number 001-40915
Entity Registrant Name PepperLime Health Acquisition Corporation
Entity Central Index Key 0001873324
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 548 Market Street
Entity Address, Address Line Two Suite 97425
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 415
Local Phone Number 263-9939
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Unitseachconsistingofone Class Aordinaryshare Dollar 0. 0001parvalueandonehalfofoneredeemable [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant
Trading Symbol PEPLU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A ordinary shares
Trading Symbol PEPL
Security Exchange Name NASDAQ
Warrantseachwholewarrantexercisableforone Class Aordinaryshares [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
Trading Symbol PEPLW
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pepperlimehealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pepl-20240220.xsd pepl-20240220_def.xml pepl-20240220_lab.xml pepl-20240220_pre.xml tm247248d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm247248d1_8k.htm": { "nsprefix": "PEPL", "nsuri": "http://pepperlimehealth.com/20240220", "dts": { "schema": { "local": [ "pepl-20240220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "pepl-20240220_def.xml" ] }, "labelLink": { "local": [ "pepl-20240220_lab.xml" ] }, "presentationLink": { "local": [ "pepl-20240220_pre.xml" ] }, "inline": { "local": [ "tm247248d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 66, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://pepperlimehealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247248d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247248d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "PEPL_UnitseachconsistingofoneClassAordinaryshareDollar0.0001parvalueandonehalfofoneredeemableMember": { "xbrltype": "domainItemType", "nsuri": "http://pepperlimehealth.com/20240220", "localname": "UnitseachconsistingofoneClassAordinaryshareDollar0.0001parvalueandonehalfofoneredeemableMember", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Unitseachconsistingofone Class Aordinaryshare Dollar 0. 0001parvalueandonehalfofoneredeemable [Member]" } } }, "auth_ref": [] }, "PEPL_WarrantseachwholewarrantexercisableforoneClassAordinarysharesMember": { "xbrltype": "domainItemType", "nsuri": "http://pepperlimehealth.com/20240220", "localname": "WarrantseachwholewarrantexercisableforoneClassAordinarysharesMember", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrantseachwholewarrantexercisableforone Class Aordinaryshares [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pepperlimehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-027499-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-027499-xbrl.zip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end XML 17 tm247248d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001873324 2024-02-20 2024-02-20 0001873324 PEPL:UnitseachconsistingofoneClassAordinaryshareDollar0.0001parvalueandonehalfofoneredeemableMember 2024-02-20 2024-02-20 0001873324 us-gaap:CommonClassAMember 2024-02-20 2024-02-20 0001873324 PEPL:WarrantseachwholewarrantexercisableforoneClassAordinarysharesMember 2024-02-20 2024-02-20 iso4217:USD shares iso4217:USD shares false 0001873324 00-0000000 8-K 2024-02-20 PepperLime Health Acquisition Corporation E9 001-40915 548 Market Street Suite 97425 San Francisco CA 94104 415 263-9939 false false false false Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant PEPLU NASDAQ Class A ordinary shares PEPL NASDAQ Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 PEPLW NASDAQ true false